WASHINGTON, Feb 26 (Reuters) - Drug manufacturer Hikma Pharmaceuticals Plc will sell the rights and assets of two generic drugs and relinquish its U.S. marketing rights to a third generic drug in order to settle Federal Trade Commission charges that Hikma's proposed $2 billion acquisition of Roxane would likely be anticompetitive, the FTC said on Friday.
Read more
No comments:
Post a Comment